Skip to main content
. Author manuscript; available in PMC: 2009 Jun 12.
Published in final edited form as: Vaccine. 2007 Jun 4;25(29):5290–5300. doi: 10.1016/j.vaccine.2007.05.010

Table 5.

Lymphoproliferative response

HASPB1 H1 HASPB1+H1 Montanide MML MPL Control
Week 0
 SLA 1.12 ± 0.8 1.24 ± 0.3 0.97 ± 0.3 1.16 ± 0.4 1.22 ± 0.6 0.98 ± 0.2 1.27 ± 0.4
 ConA 7.32 ± 3.6 7.67 ± 2.7 8.17 ± 3.2 8.18 ± 1.8 7.62 ± 2.0 7.42 ± 2.28 8.50 ± 2.8
Week 8
 SLA 0.97 ± 0.1 1.39 ± 0.4 1.00 ± 0.4 1.30 ± 0.3 1.33 ± 0.4 1.18 ± 0.4 1.07 ± 0.33
 ConA 6.51 ± 4.0 7.20 ± 2.8 12.12 ± 10.5 14.73 ± 11.7 10.97 ± 9.9 18.0 ± 5.8 10.2 ± 6.1
Week 48
 SLA 1.00 ± 0.3 1.02 ± 0.5 1.32 ± 0.9 1.12 ± 0.39 0.94 ± 0.5 1.13 ± 0.3 1.28 ± 0.2
 ConA 2.59 ± 1.0 4.97 ± 2.9 2.88 ± 1.16 6.31 ± 2.3 3.9 ± 1.1 3.81 ± 0.1 3.45 ± 0.9

The results are expressed as the mean stimulation index ± S.D. Lymphoproliferative assays were carried out following immunization (week 0) and at weeks 8 and 48 after experimental infection.